FBL15 Inhibitors
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically binds to FKBP12 and the resulting complex inhibits mTOR (mammalian target of rapamycin), which is a downstream regulator of FBL15 in the PI3K/AKT signaling pathway. The inhibition of mTOR leads to a decrease in FBL15 activity due to reduced phosphorylation and activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which play a crucial role in the PI3K/AKT/mTOR pathway, upstream of FBL15. By inhibiting PI3K, LY294002 decreases the activation of AKT and subsequently mTOR, leading to reduced activity of FBL15. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a selective inhibitor of MEK, which in turn inhibits ERK phosphorylation. ERK is a part of the MAPK signaling pathway that modulates the activity of numerous proteins including FBL15. By inhibiting MEK, PD 98059 decreases the functional activation of ERK and indirectly reduces the activity of FBL15. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. Since p38 MAPK is involved in the stress response and its pathway can intersect with pathways regulating FBL15, inhibition by SB203580 can lead to a decrease in FBL15 activity by reducing the phosphorylation signals that would typically enhance FBL15 function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is part of the MAPK signaling pathways. Inhibition of JNK activity can suppress the signaling cascades that affect the functional regulation of FBL15, leading to decreased activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family kinases, which are associated with various signaling pathways that can modulate the activity of downstream proteins like FBL15. By inhibiting Src kinases, PP2 potentially decreases the activation signals reaching FBL15. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. Similar to LY294002, it blocks PI3K activity, disrupting the PI3K/AKT/mTOR signaling pathway and leading to a reduction in the functional activity of FBL15 through decreased phosphorylation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 selectively inhibits MEK1/2, leading to a decrease in ERK1/2 activity within the MAPK pathway. Reduced ERK activity means less phosphorylation and activation of proteins that are regulated by this pathway, including FBL15. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor with broad specificity. It can inhibit Src family kinases and Bcr-Abl kinase, which are upstream regulators in signaling pathways affecting FBL15 activity. The inhibition of these kinases can reduce the phosphorylation and activation of FBL15. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib selectively inhibits epidermal growth factor receptor (EGFR) tyrosine kinase, which is implicated in the activation of several downstream signaling pathways, including those associated with FBL15 regulation. Inhibition of EGFR can lead to reduced activity of FBL15 due to lessened downstream signaling. | ||||||